Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
54.85
-0.15 (-0.27%)
At close: Mar 13, 2025, 4:00 PM
55.84
+0.99 (1.80%)
After-hours: Mar 13, 2025, 5:12 PM EST
Corcept Therapeutics Revenue
In the year 2024, Corcept Therapeutics had annual revenue of $675.04M with 39.94% growth. Corcept Therapeutics had revenue of $181.89M in the quarter ending December 31, 2024, with 34.33% growth.
Revenue (ttm)
$675.04M
Revenue Growth
+39.94%
P/S Ratio
8.39
Revenue / Employee
$1,350,080
Employees
500
Market Cap
5.79B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 675.04M | 192.67M | 39.94% |
Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CORT News
- 1 day ago - Bronstein, Gewirtz & Grossman, LLC Encourages Bronstein, Gewirtz & Grossman, LLC (CORT) Investors to Inquire about Securities Investigation - Accesswire
- 2 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Shareholders to Inquire about Securities Investigation - Accesswire
- 3 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Shareholders to Connect - Accesswire
- 3 days ago - Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension - Business Wire
- 4 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Corcept Therapeutics Incorporated (CORT) And Encourages Shareholders to Reach Out - Accesswire
- 6 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 7 days ago - Corcept Therapeutics Incorporated (CORT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 8 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Investors to Connect - Accesswire